Skip to main content
. Author manuscript; available in PMC: 2011 Nov 17.
Published in final edited form as: Clin Cancer Res. 2009 Aug 11;15(16):5267–5273. doi: 10.1158/1078-0432.CCR-09-0888

Table 3.

Clinical outcomes for rare mutations or rare combinations of mutations

Mutation(s) N Response TTP, mo OS, mo
Suspected sensitizing mutation
    L861Q 1 SD 4 8.8
    G719A 1 SD 3.9 5.2
    Exon 19 duplication 1 PR 22.1+ 22.1+
Suspected resistance mutation
    Exon 20 insertion 31 1 SD, 2 PD 1.0 (median) 1.5 (median)
Multiple mutations
    Exon 19 del + L861Q + G873E 1 SD 20.5 34.9+
    L858R + T790M 1 PD 1.9 17.5
    T790M + KRAS mutation 1 PD 0.8 0.8
    Exon 19 del + KRAS mutation 1 SD 25.8 44.7+
    V802I + KRAS mutation 1 PD 0.9 4.0
    G719A + G779C 1 PR 2.9+ 2.9+

Abbreviations: SD, stable disease; PR, partial response; PD, progressive disease.